Testing of a second and higher dose of ACI-35.030, a potential Alzheimer’s vaccine, is now beginning in a Phase 1b/2a clinical trial, AC Immune announced. Positive interim safety, tolerability, and specificity results from an initial dosing group of patients allowed the trial to advance to its medium dosing regimen, the company reported in a press release. ACI-35.030, being developed in collaboration with Janssen Pharmaceuticals, mimics the structure of the toxic version of the tau protein — phosphorylated tau — that underlies…
You must be logged in to read/download the full post.
The post Trial of Potential Alzheimer’s Vaccine Advances to Medium Dose Group appeared first on BioNewsFeeds.